Angelo Elmi

Angelo Elmi

Auto-generated profile, based on publicly available information

Angelo Elmi

Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, The George Washington University, 950 New Hampshire Avenue NW, Suite 200, Washington, DC 20052, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2014 in AIDS and Behavior
Verified
Journal Article
Open access
PDF file
DBDebra A. Benator
Debra A. Benator
AEAngelo Elmi
Angelo Elmi
MRManuel D. Rodriguez
Manuel D. Rodriguez
HGHoward B. Gale
Howard B. Gale
VKVirginia L. Kan
Virginia L. Kan
LSLeah Squires
Leah Squires
Although the majority of HIV-infected patients who begin potent antiretroviral therapy should expect long-term virologic suppression, the realities in practice are less certain. Durability of viral suppression was examined to define the best timing of targeted adherence strategies and intensive viral load monitoring in an urban clinic population with multiple challenges to ART adherence. We examined the risk of viral rebound for patients who achieved two consecutive viral loads lower than the lower limit of quantification (LLOQ) within 390 days. For 791 patients with two viral loads below the LLOQ, viral rebound >LLOQ from the first viral load was 36.9 % (95 % CI 32.2–41.6) in the first year, 26.9 % (95 % CI 21.7–32.1) in the year following one year of viral suppression, and 24.6 % (95 % CI 18.4–30.9) in the year following 2 years of viral suppression. However, for patients with CD4 ≥300 cells/µl who had 3–6 years of virologic suppression, the risk of viral rebound was very low. At the population level, the risk of viral rebound in a complex urban clinic population is surprisingly high even out to 3 years. Intensified monitoring and adherence efforts should target this high risk period. Thereafter, confidence in truly durable virologic suppression is improved.

8 April 2020 in Journal of Quantitative Analysis in Sports
Verified
Journal Article
Closed access
PDF file
ACAvinash Chandran
Avinash Chandran
LDLoretta DiPietro
Loretta DiPietro
Heather YoungHeather Young
Heather Young
AEAngelo Elmi
Angelo Elmi
In assessments of sports-related injury severity, time loss (TL) is measured as a count of days lost to injury and analyzed using ordinal cut points. This approach ignores various athlete and event-specific factors that determine the severity of an injury. We present a conceptual framework for modeling this outcome using univariate random effects count or survival regression. Using a sample of US collegiate soccer-related injury observations, we fit random effects Poisson and Weibull Regression models to perform “severity-adjusted” evaluations of TL, and use our models to make inferences regarding the recovery process. Injury site, injury mechanism and injury history emerged as the strongest predictors in our sample. In comparing random and fixed effects models, we noted that the incorporation of the random effect attenuated associations between most observed covariates and TL, and model fit statistics revealed that the random effects models (AICPoisson = 51875.20; AICWeibull-AFT = 51113.00) improved model fit over the fixed effects models (AICPoisson = 160695.20; AICWeibull-AFT = 53179.00). Our analyses serve as a useful starting point for modeling how TL may actually occur when a player is injured, and suggest that random effects or frailty based approaches can help isolate the effect of potential determinants of TL.

5 September 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
ASAllison C. Sylvetsky
Allison C. Sylvetsky
HMHailey R. Moore
Hailey R. Moore
XZXinyu Zhu
Xinyu Zhu
JKJasmine H. Kaidbey
Jasmine H. Kaidbey
LKLeyi Kang
Leyi Kang
RSRandi Streisand
Randi Streisand
Low-calorie sweeteners (LCS) are commonly consumed by children with type 1 diabetes (T1D), yet their role in cardiometabolic health is unclear. This study examined the feasibility, acceptability, and preliminary effects of 12 weeks of LCS restriction among children with T1D. Children (n = 31) with T1D completed a two-week run-in (n = 28) and were randomly assigned to avoid LCS (LCS restriction, n = 15) or continue their usual LCS intake (n = 13). Feasibility was assessed using recruitment, retention, and adherence rates percentages. Acceptability was assessed through parents completing a qualitative interview (subset, n = 15) and a satisfaction survey at follow-up. Preliminary outcomes were between-group differences in change in average daily time-in-range (TIR) over 12 weeks (primary), and other measures of glycemic variability, lipids, inflammatory biomarkers, visceral adiposity, and dietary intake (secondary). Linear regression, unadjusted and adjusted for age, sex, race, and change in BMI, was used to compare mean changes in all outcomes between groups. LCS restriction was feasible and acceptable. No between-group differences in change in TIR or other measures of glycemic variability were observed. However, significant decreases in TNF-alpha (−0.23 ± 0.08 pg/mL) and improvements in cholesterol (−0.31 ± 0.18 mmol/L) and LDL (−0.60 ± 0.39 mmol/L) were observed with usual LCS intake, compared with LCS restriction. Those randomized to LCS restriction did not report increases in total or added sugar intake, and lower energy intake was reported in both groups (−190.8 ± 106.40 kcal LCS restriction, −245.3 ± 112.90 kcal usual LCS intake group). Decreases in percent energy from carbohydrates (−8.5 ± 2.61) and increases in percent energy from protein (3.2 ± 1.16) and fat (5.2 ± 2.02) were reported with usual LCS intake compared with LCS restriction. Twelve weeks of LCS restriction did not compromise glycemic variability or cardiometabolic outcomes in this small sample of youth with T1D. Further examination of LCS restriction among children with T1D is warranted.

28 February 2018 in Biometrics
Verified
Journal Article
Closed access
PDF file
AEAngelo F. Elmi
Angelo F. Elmi
KGKatherine L. Grantz
Katherine L. Grantz
PAPaul S. Albert
Paul S. Albert

1 July 2021 in Contemporary Clinical Trials
Verified
Journal Article
Open access
ASAllison C. Sylvetsky
Allison C. Sylvetsky
HMHailey R. Moore
Hailey R. Moore
JKJasmine H. Kaidbey
Jasmine H. Kaidbey
SHSabrina E. Halberg
Sabrina E. Halberg
FCFran R. Cogen
Fran R. Cogen
RSRandi Streisand
Randi Streisand
Low-calorie sweeteners (LCSs) provide sweetness without sugar or calories and are used to replace added sugars by many children with type 1 diabetes (T1D). However, the role of LCSs in diabetes management and cardiometabolic health is unclear. The Diabetes Research in Kids Study (DRINK-T1D) aims to investigate effects of LCS restriction on glycemic variability, visceral adiposity, lipid profiles, and systemic inflammation among children 6-12 years old with T1D. Children with T1D, who report habitual consumption of foods and beverages containing LCSs, are recruited from the Washington Nationals Diabetes Care Complex (DCC) at Children's National Hospital (CNH) in Washington, DC. Following a phone screening and two-week run-in period involving continuation of usual LCS intake, children are randomized to 12 weeks of LCS restriction (replacement of diet beverages with still or sparkling water and avoidance of other sources of LCSs) or continued usual LCS intake (control). The primary outcome is the difference in change in glycemic variability in the LCS restriction group versus the control group. Change in glycemic variability will be assessed as the difference in daily average time-in-range (TIR), measured using continuous glucose monitoring (CGM) during two weeks at the end of the 12-week intervention, compared with during the two-week run-in period prior to randomization. Participants also complete a variety of anthropometric, metabolic, dietary, and behavioral assessments throughout the 14-week study. DRINK-T1D is an innovative, randomized controlled trial, evaluating effects of LCS restriction on glycemic variability and cardiometabolic health in children with T1D. Findings of DRINK-T1D will support or challenge the common practice of recommending LCS use in this patient population and will have clinically relevant implications for pediatric T1D management. ClinicalTrials.gov Identifier NCT04385888.

4 September 2014 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
AEAngelo Elmi
Angelo Elmi
SRSarah J. Ratcliffe
Sarah J. Ratcliffe
WGWensheng Guo
Wensheng Guo